Modified Delphi Consensus Guidelines for Pelvic Floor Botulinum Toxin Injection.
Abstract
[IMPORTANCE] Myofascial pelvic pain (MPP) is an under-treated etiology of pelvic pain, presenting with pelvic floor tender points and/or increased tension. While limited data support off-label use of pelvic floor botulinum toxin (BTA) injections for refractory MPP, clinical guidance on its utilization is lacking.
[OBJECTIVE] We sought to develop consensus-based guidelines for pelvic floor BTA injection.
[STUDY DESIGN] We identified 46 potential experts in the use of pelvic floor BTA injection based on research, clinical volume, and publication of patient-facing materials, 18 of whom agreed to participate. Consensus, defined as at least 70% agreement or disagreement, was determined through 3 rounds of electronic surveys using a modified Delphi method between September 2023 and July 2024.
[RESULTS] A total of 15 practitioners completed the first survey, with most based in the United States (93%), working in academic settings, with Obstetrics and Gynecology training (85%). Expert consensus supports that BTA injection is a third-line therapy for high-tone pelvic floor dysfunction and myofascial pelvic pain. Its use may also be considered for involuntary vaginismus, vestibulodynia, and anismus/dyssynergic defecation. Preprocedural examination is sufficient to localize sites and should palpate the puborectalis, pubococcygeus, iliococcygeus, and obturator internus. Injections of 100-200 units total should focus on areas of increased tenderness/hypertonicity; however, for global symptoms or inability to tolerate examination, templated injections may be used. Experts did not support performing local anesthetic injections to predict responses. Injection is performed transvaginally with each muscle group receiving 20-50 units BTA in divided 1-2 mL injections. Injections are performed bilaterally. Patients should be followed by quantitative pain assessments with repeat injections as needed.
[CONCLUSIONS] Using a modified Delphi method, we describe expert consensus-based guidelines for pelvic floor BTA injection to provide practical guidance for its use.
[OBJECTIVE] We sought to develop consensus-based guidelines for pelvic floor BTA injection.
[STUDY DESIGN] We identified 46 potential experts in the use of pelvic floor BTA injection based on research, clinical volume, and publication of patient-facing materials, 18 of whom agreed to participate. Consensus, defined as at least 70% agreement or disagreement, was determined through 3 rounds of electronic surveys using a modified Delphi method between September 2023 and July 2024.
[RESULTS] A total of 15 practitioners completed the first survey, with most based in the United States (93%), working in academic settings, with Obstetrics and Gynecology training (85%). Expert consensus supports that BTA injection is a third-line therapy for high-tone pelvic floor dysfunction and myofascial pelvic pain. Its use may also be considered for involuntary vaginismus, vestibulodynia, and anismus/dyssynergic defecation. Preprocedural examination is sufficient to localize sites and should palpate the puborectalis, pubococcygeus, iliococcygeus, and obturator internus. Injections of 100-200 units total should focus on areas of increased tenderness/hypertonicity; however, for global symptoms or inability to tolerate examination, templated injections may be used. Experts did not support performing local anesthetic injections to predict responses. Injection is performed transvaginally with each muscle group receiving 20-50 units BTA in divided 1-2 mL injections. Injections are performed bilaterally. Patients should be followed by quantitative pain assessments with repeat injections as needed.
[CONCLUSIONS] Using a modified Delphi method, we describe expert consensus-based guidelines for pelvic floor BTA injection to provide practical guidance for its use.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 해부 | MPP
→ Myofascial pelvic pain
|
scispacy | 1 | ||
| 해부 | puborectalis
|
scispacy | 1 | ||
| 해부 | pubococcygeus
|
scispacy | 1 | ||
| 해부 | iliococcygeus
|
scispacy | 1 | ||
| 해부 | obturator internus
|
scispacy | 1 | ||
| 해부 | muscle
|
scispacy | 1 | ||
| 해부 | BTA
|
scispacy | 1 | ||
| 합병증 | pelvic
|
scispacy | 1 | ||
| 합병증 | pelvic floor botulinum
|
scispacy | 1 | ||
| 합병증 | myofascial pelvic
|
scispacy | 1 | ||
| 약물 | third-line
|
scispacy | 1 | ||
| 약물 | [IMPORTANCE] Myofascial pelvic pain (
|
scispacy | 1 | ||
| 약물 | [OBJECTIVE]
|
scispacy | 1 | ||
| 약물 | [RESULTS] A
|
scispacy | 1 | ||
| 약물 | BTA
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 질환 | Pelvic Floor Botulinum
|
scispacy | 1 | ||
| 질환 | Myofascial pelvic pain
|
scispacy | 1 | ||
| 질환 | pelvic pain
|
C0030794
Pelvic Pain
|
scispacy | 1 | |
| 질환 | floor botulinum toxin
|
scispacy | 1 | ||
| 질환 | high-tone pelvic floor dysfunction
|
scispacy | 1 | ||
| 질환 | involuntary vaginismus
|
scispacy | 1 | ||
| 질환 | vestibulodynia
|
C0269084
Vulvar Vestibulitis
|
scispacy | 1 | |
| 질환 | anismus/dyssynergic defecation
|
scispacy | 1 | ||
| 질환 | tenderness/hypertonicity
|
scispacy | 1 | ||
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 질환 | Pelvic Floor Botulinum Toxin
|
scispacy | 1 | ||
| 질환 | BTA
|
scispacy | 1 | ||
| 기타 | pelvic floor
|
scispacy | 1 | ||
| 기타 | pelvic floor BTA
|
scispacy | 1 | ||
| 기타 | Patients
|
scispacy | 1 |
MeSH Terms
Humans; Delphi Technique; Consensus; Female; Pelvic Floor; Pelvic Pain; Neuromuscular Agents; Practice Guidelines as Topic; Botulinum Toxins, Type A; Botulinum Toxins; Myofascial Pain Syndromes
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.